Diffuse Alveolar Hemorrhage in IgA Vasculitis with an Atypical Presentation

Yuhei Ito¹, Machiko Arita¹, Shogo Kumagai¹, Reoto Takei¹, Maki Noyama¹, Fumiaki Tokioka¹, Takumi Nagamoto², Chieko Kawakita³, Kenichiro Asano⁴, Chika Okita⁵ and Tadashi Ishida¹

Abstract:
IgA vasculitis (IgAV) commonly occurs in young children, who present with a tetrad of purpura, abdominal pain, arthralgia and nephritis. Diffuse alveolar hemorrhage (DAH) is a rare complication of IgAV. We herein report an adult case of IgAV with a presentation of DAH and nephritis (pulmonary renal syndrome, PRS), but without other typical manifestations, such as purpura, abdominal pain and arthralgia. A 33-year-old man presented with hemoptysis and a low-grade fever and was diagnosed to have IgAV based on the results of a renal biopsy. Treatment with corticosteroids, cyclophosphamide, and plasmapheresis was effective. IgAV should therefore be considered in the differential diagnosis of adult PRS.

Key words: Henöch-Schonlein purpura, IgA vasculitis, diffuse alveolar hemorrhage, pulmonary-renal syndrome, adult, plasmapheresis

(Intern Med Advance Publication)
(DOI: 10.2169/internalmedicine.8984-17)

Introduction
IgA vasculitis (IgAV) is a vasculitic disorder which is characterized by the deposition of IgA1-dominant immune complex in small vessels. The formerly-used nomenclature, “Henöch-Schonlein purpura (HSP)”, was replaced by “IgA vasculitis” in the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of vasculitis (1). IgAV usually involves the skin and gastrointestinal tract and frequently results in arthritis, but complications with diffuse alveolar hemorrhage (DAH) are rare. We herein describe a patient with IgAV who presented with pulmonary-renal syndrome (PRS), in which there were clinical manifestations of DAH in the lung and nephritis in the kidneys, but without any typical manifestations of IgAV, such as purpura, abdominal pain, and arthralgia. Based on the diagnosis of PRS, systemic vasculitic disorders such as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and anti-glomerular basement disease were initially suspected. However, the diagnosis of IgAV was made based on the findings of renal biopsy specimens. Namely, mesangiproliferative glomerulonephritis with cellular crescents and mesangial IgA deposition were the pathognomonic features of vasculitic disorder in this patient.

Case Report
A 33-year-old man was referred to our hospital because of hemoptysis and a low-grade fever which had lasted for a week. He had no arthralgia, abdominal pain, or skin lesions. He did not have any particular past medical history. He did not take any regular medication. He took loxoprofen sodium hydrate, and expectorant orally after hemoptysis and a low-grade fever occurred. At presentation, the patient’s vital status was as follows; height: 165 cm; weight: 90 kg; body temperature: 37.5°C. Physical examination revealed no purpura, abdominal pain, or arthralgia. Chest X-ray showed a new infiltrate in the right lower lobe. Laboratory findings were as follows: white blood cell count: 7,500/μL (neutrophil: 80.0%), hemoglobin: 14.5 g/dL, platelet count: 250,000/μL, C-reactive protein: 0.8 mg/dL, serum creatinine: 0.9 mg/dL, and anti-nuclear antibody: negative. Renal biopsy performed revealed a mesangioproliferative glomerulonephritis with cellular crescents and mesangial IgA deposition. Based on the diagnosis of PRS, systemic vasculitic disorders such as AAV and anti-glomerular basement disease were initially suspected. However, the diagnosis of IgAV was made based on the findings of renal biopsy specimens. Namely, mesangioproliferative glomerulonephritis with cellular crescents and mesangial IgA deposition were the pathognomonic features of vasculitic disorder in this patient.
mass index (BMI): 33 kg/m²; blood pressure: 179/123 mmHg; body temperature: 37.3°C; heart rate: 104/min; respiratory rate: 16/min; and percutaneous oxygen saturation: 94% with 24% oxygen inhalation via a nasal cannula. Physical examination revealed no skin lesions or abnormal respiratory sounds. Laboratory findings were as follows: total protein: 7.6 g/dL; albumin 3.4 g/dL; alanine aminotransferase: 21 IU/L; aspartate aminotransferase: 23 IU/L; lactate dehydrogenase: 314 IU/L; blood urea nitrogen: 59 mg/dL; creatinine: 7.23 mg/dL; C-reactive protein: 6.36 mg/dL; white blood cell count: 10,200/μL with 80.4% neutrophils and 11.1% lymphocytes; red blood cell count: 3.06x10⁶/μL; hemoglobin 9.2 g/dL; hematocrit: 26.7%; and platelet count: 23.9x10⁵/μL. His serum electrolyte concentration was normal. An arterial blood gas analysis indicated a pH of 7.413, PaCO₂ 36.8 mmHg, PaO₂ 74.4 mmHg, and HCO₃⁻ 23.1 mmol/L with 24% oxygen inhalation via a nasal cannula.

Urinalysis indicated that proteinuria was (2+) and microscopic hematuria was (3+) and red blood cells were 10–19/high power field. The red blood cells in the urine were mostly dysmorphic and granular casts were observed. The urine protein to creatinine ratio was 1.24 g/g-Cre. Chest radiography revealed the presence of bilateral pulmonary infiltrates, and a chest CT scan revealed diffuse ground-glass opacity at all levels of the lung fields (Fig. 1). Bronchoscopy was performed and bronchoalveolar lavage (BAL) samples indicated an alveolar hemorrhage. Intravenous methylprednisolone (mPSL) of 1 g per a day were administered for three consecutive days along with intravenous pulse cyclophosphamide of 750 mg. Plasmapheresis for three consecutive days was started since we suspected a systemic vasculitic disorder such as AAV and anti-glomerular basement disease. On day two, anti-nuclear antibody (ANA) and ANCA which were examined by immunofluorescence (IF) were reported to be negative. On day five, proteinase-3 ANCA, myeloperoxidase-specific ANCA examined by enzyme-linked immunosorbent assays (ELISA) and anti-glomerular basement membrane antibody were reported to be negative. On day six, a renal biopsy was performed, which demonstrated diffuse mesangioproliferative glomerulonephritis with cellular crescents in the kidney tissue. An immunofluorescence study demonstrated mesangial deposition of IgA and C3 in the glomerulus (Fig. 2). Electron microscopy showed electron-dense deposits consistent with immune complexes in the mesangial area. We made a diagnosis of IgA, and oral prednisolone (85 mg/day, 1 mg/kg/day) was administered after intravenous mPSL. This treatment regimen resulted in an improvement of IgAV which was observed on chest radiography. On day seven, his percutaneous oxygen saturation recovered to 94% with no oxygen inhalation therapy. On day 26, a colonoscopy was performed and the tissue of the intestinal wall was shown to be intact by the biopsy specimens, which eliminated the possibility of a gastrointestinal lesion as a complication of IgAV. Considering the severity of IgAV with DAH, additional intravenous cyclophosphamide of 600 mg was administered on day 38 and oral prednisolone was gradually tapered to 55 mg/day before the patient was discharged on day 39.

**Discussion**

According to the findings of this case, we learned two
important clinical facts. The first was that IgAV can present
PRS in adults without showing other typical manifestations,
such as purpura, abdominal pain and arthralgia. Secondly,
treatment with combined corticosteroids, cyclophosphamide,
and plasmapheresis therapy was effective even though DAH
can be a refractory and life-threatening complication.

We consider this case of IgAV to be rare because this pa-
tient was an adult who presented initially with PRS, and
without any other typical manifestations of IgAV such as
purpura, arthralgia, and abdominal pain. HSP (IgAV) pri-
marily occurs in young children with a peak incidence be-
 tween 4-7 years (2). Purpura occurs in almost every patient.
Arthralgia occurs in approximately two third of cases. Gas-
trointestinal involvement, including abdominal pain, occurs
in approximately two third of cases (3). Previous studies
showed that IgAV is generally benign and self-limited in
children and more severe in adults (4). Adults had a lower
frequency of abdominal pain and fever, and a higher fre-
quency of joint symptoms at disease onset (5). Rajagopala et
al. reported the development of DAH in HSP (IgAV) in
older children and adult patients. The mean age of onset
was 16.5 years (6). Since our case was a 33-year-old man
and no skin lesions were observed, IgAV was not initially
suspected. From previous reports, a prevalence of 0-5% is
suggested for DAH which develops in HSP (IgAV) (7-11).
A total of 35 patients with IgAV who presented with DAH
showed concurrent purpura at the time of disease onset in
previous reports (6). Only one report described HSP (IgAV)
complicated with DAH in the absence of purpura, gastroin-
testinal tract lesions, and arthritis. In that report, however,
the patient developed DAH 11 years after the diagnosis of
HSP (IgAV), and he exhibited typical purpura at the time of
onset of the disease (12). Our case is rare in that he did not
exhibit purpura throughout the entire clinical course. IgAV
should be considered in the differential diagnosis of PRS in
adults even if other typical manifestations of IgAV, such as
purpura, arthralgia, and abdominal pain are not observed.

Rajagopala et al. reported 18 cases of HSP (IgAV) with
DAH who underwent renal biopsy. Most of these patients
showed various degrees of glomerulonephritic change in
light microscopy. Furthermore, immunofluorescence was
performed in 16 patients, of which 15 demonstrated a de-
position of IgA and C3 (6). Glomerulonephritis, which is in-
distinguishable from IgA nephritis, may occur in IgAV (1).
In our patient, the diagnosis of IgAV was made based on
findings of mesangiproliferative glomerulonephritis with
cellular crescents and mesangial IgA deposition. Another
possible examination for the findings of renal biopsy in this
case is that IgA nephropathy was superimposed on or over-
lapping the ANCA-negative AAV. Although ANCA was
negative by either indirect IF or the ELISA method, this
finding did not rule out the presence of AAV (1). Mark et
al. reported 6 cases of ANCA associated crescent glomeru-
lonephritis with mesangial IgA deposits (13).

DAH can be a life-threatening complication of IgAV
(HSP) and previous reports have shown a high mortality rate
of 27.8% (6). Rajagopala et al. conducted a systematic re-
view and reported that as for the treatment of DAH in HSP
(IgAV), combination therapy with corticosteroids and im-
umosuppressants are reported to be most effective. Among
36 patients of DAH in HSP (IgAV), treatment was as fol-
 lows: oral steroids alone (11 patients), intravenous mPSL
pulse alone (11 patients), combination therapy with corti-
costeroids and immunosuppressants, such as cyclophos-
phamide, azathioprine, mycophenolate mofetil, or cy-
closporine A (11 patients), and no treatment (3 patients).
The mortality rate was 27.2% for oral steroids, 27.2% for
intravenous mPSL pulse alone, 9% for combination therapy,
and 100% for no treatment (6). As immunosuppressants
added to corticosteroids for the treatment of severe IgAV,
cyclophosphamide has been used by analogy with other se-
vere autoimmune diseases (3). However, the addition of
cyclophosphamide to corticosteroids for the treatment of se-
vere IgAV still remains controversial. Pillebout et al. com-
pared corticosteroids with or without cyclophosphamide in
adults with severe IgAV, in a 12-month, multicenter, pro-
spective, open-label trial, and reported that no difference
was found between the two groups (remission rate, renal
outcomes, deaths, and adverse events) (14). In this case,
considering the high mortality rate of DAH in IgAV, we
continued cyclophosphamide along with corticosteroids. Pre-
vious studies suggest that patients with either systemic IgAV

Figure 2. Renal biopsy. PAS stain indicates mesangioproliferative glomerulonephritis with cellular
crescents (A). Direct immunofluorescence microscopy shows mesangial IgA (B) and C3 (C) deposi-
tion. Original magnification: ×400. PAS: Periodic acid-Schiff

(A) (B) (C)
or renal limited IgA nephropathy have abnormally-glycosylated IgA1 and possibly glycanspecific IgG antibodies that form circulating IgA1-anti-IgA1 immune complexes, which cause inflammation and damage to the organs (15, 16). Hattori et al. reported that plasmapheresis was effective for improving the prognosis of children with rapidly-progressive glomerulonephritis which was caused by HSP (IgAV) (17). Augasto et al. also reported that the combination of plasmapheresis and corticosteroids in adults with severe forms of HSP (IgAV) was associated with a rapid improvement and good-long term outcome (18). The mechanism by which plasmapheresis may improve patients with severe HSP (IgAV) is largely unknown. One possible mechanism is the removal of pathogenic circulating IgA-containing immune complexes by plasmapheresis (19). Another possible mechanism is the removal of proinflammatory and procoagulatory substances by plasmapheresis. These reports suggest that plasmapheresis is a reasonable adjuvant therapy for treating IgAV patients with DAH. In our experience, the patient was immediately treated with a combination of intravenous mPSL, cyclophosphamide, oral steroids and plasmapheresis, given that we initially suspected a systemic vasculitic disorder. The results of a renal biopsy revealed that IgAV was the cause of PRS and indicated that the continuation of the initial therapy in this patient was reasonable. Since there is not enough data available regarding the optimal treatment for severe IgAV, the diagnosis of IgAV itself did not have great impact on the treatment policy in this case. Further randomized controlled trials regarding the optimal treatment for severe IgAV are thus needed.

In conclusion, our case demonstrated that IgAV can manifest as PRS in adults without showing other typical manifestations, such as purpura, abdominal pain and arthralgia. Treatment with corticosteroids, cyclophosphamide, and plasmapheresis was effective. We must be aware that IgAV can result in PRS in adults without showing any other typical manifestations. In these cases, a renal biopsy is essential for making an accurate diagnosis of IgAV. Further studies are required to establish the optimal therapeutic strategies for this life-threatening complication of IgAV.

The authors state that they have no Conflict of Interest (COI).

References


© The Japanese Society of Internal Medicine
Intern Med Advance Publication
DOI: 10.2169/internalmedicine.8984-17